- How our “new normal” is affecting our critical materials procurement and how do we adapt for the future?
- Examining how the proposed nationalization of our supply chains will affect risk management and operations planning
- What does post-COVID19 Supply Chain robustness look like?
- How do novel modalities (mRNA, Cell & Gene Therapy) with already existing supply chain challenges cope with these new global constraints?
- How will high volume ultra cold chain products affect existing specialized ultra cold chain logistics?
- Seismic shifts and emerging fault lines create lasting affects, what are they and how do they shape our industry in the years to come?
Chairman at Acepodia
& Founding Board Director at Sana Biotechnology
Dr. Patrick Y. Yang has over 35 years leadership experience in technology, manufacturing, supply chain, and operational management functions in General Electric, Merck, Genentech, Roche, and Juno Therapeutics.
He was Executive Vice President and Global Head of Roche Pharmaceuticals Technical Operations based in Basel, Switzerland from January 2010 to March 2013. In this role, he was accountable for Roche’s pharmaceutical and biotech manufacturing operations, and process development. He and as previously Executive Vice President of Product Operations of Genentech, based in South San Francisco. Dr. Yang worked for Genentech for 10 years, from 2003 until his retirement in October 2013.
Prior to joining Genentech, Dr. Yang spent 11 years at Merck & Co. in various leadership positions including Vice President, Supply Chain Management, and Vice President, Asia/Pacific Operations.
Before joining Merck in 1992, Dr. Yang spent 12 years at General Electric (1980-1992), serving in research, engineering, technology, and manufacturing leadership roles with increasing scope of responsibilities.
Dr. Yang holds a Ph.D. degree in engineering from Ohio State University, Columbus, Ohio.
He a member of Board of Directors of Tesoro Corporation, Codexis, Celladon, Amyris, and PharmaEssentia.
Chief Technology Officer
Dr. Alison Moore is Chief Technical Officer at Allogene Therapeutics. Prior to this role, Moore served as senior vice president, Process Development,in Amgen Operations. Moore was previously vice president, Process and Product Engineering (P&PE), where she was responsible for Process Development, Clinical Operations and Global Operations Planning. Moore served as vice president, Corporate Manufacturing, overseeing Supply Chain, Contract Manufacturing, Global Distribution, Manufacturing Technologies, and Operations Risk Management. Before taking on this position, she was vice president, Site Operations at Amgen’s Fremont, California, manufacturing facility (AFR).
Before heading up the AFR facility, Moore was a director in Chemistry, Manufacturing and Controls Regulatory Affairs at Genentech. Prior to her time at Genentech, Moore had previously spent nine years at Amgen in various positions of increasing responsibility within the Process Development organization.
Moore holds a Ph.D. in Cell Biology from Manchester University, England, and a bachelor’s in Pharmacology with Honors from Manchester University, England. Following her doctoral degree work at Manchester University, she was a Postdoctoral Research Fellow at the Medical University of Lübeck, Germany, and at Genentech.
SVP Global Supply Chain Management
Mr. Craig Kennedy is Senior Vice President of Transformation and Supply Chain Management. Craig has a proven track record of driving change and operations improvement at Merck. Craig will enable our transformational efforts focused on Fortify Plant to Patient integrating financial planning, MMD’s Digital strategy, accelerating Merck Production System, Merck for Mothers, Enterprise Resiliency Modernization and Enterprise Risk Management positioning Merck for the long term.
Since joining Merck in 1996, Craig’s Merck experience has broadly encompassed Regional operations management, plant management and direct manufacturing operations, change management functions, SAP implementation, Supply Chain and inventory management, capacity management and materials management.
Before coming to Merck, Craig worked for a consulting firm, Professional Systems Development, as a project manager and consultant specializing in computer systems and operations improvement supporting companies located in Asia Pacific, the Middle East, Africa, Western and Eastern Europe and the U.S.
Craig graduated from the University of Sydney, Australia with a degree in computer science and pure mathematics.
Craig has lived and worked in many different countries and cultures around the world, and lives with his family in Princeton, NJ.
VP Global Supply Chain
LeAnn Pipkins joined Gilead in 2019 as Vice President of Global Supply Chain and has been focused on leading Gilead’s transformation in integrated planning.
Before Gilead, LeAnn spent 20 years in the biopharmaceutical industry in roles of increasing responsibility at Pharmacia/Pfizer and Genentech/Roche. She has worked in global operations in supply chain, strategy and regulatory. Prior to joining the biopharmaceutical industry, LeAnn worked in the fine chemical industry as a process improvement engineer for Eastman Chemical.
LeAnn holds bachelor’s degrees in Economics and Chemical Engineering from Texas A&M University and an MBA from the University of Chicago.
VP, Supply Chain and External Manufacturing
Stephen Hardt is the Vice President Supply Chain and External Manufacturing for Allogene Therapeutics, overseeing a broad network of contract manufacturers and suppliers and leading Allogene’s planning, logistics and distribution functions. Stephen has over 25 years of experience in technical operations, supply chain strategy, manufacturing and portfolio management. Prior to joining Allogene, he worked for Genentech where he held various global leadership roles most recently as the Vice President of Technical Product Management and Network Strategy. In this role, Stephen developed and executed product strategies for a portfolio of over 40 products, led the biologic and small molecule CMC team system and his team oversaw numerous global product launches including Tecentriqâ, Ocrevusâ and Hemlibraâ. At Genentech, Stephen was also the Global Head of Contract Manufacturing Operations, providing leadership for an extensive external network of drug substance, drug product and clinical manufacturing sites. Prior to joining Genentech, Steve held various senior roles across the biotech and diagnostic industries. Steve holds a bachelor’s degree in biology from the University of California, San Diego.
VP Global Supply Chain
Som Chattopadhyay serves as Vice President, Global Supply Chain Organization. Reporting to Executive Vice-President of Operations, primary responsibilities include supply of medicines to patients in a safe, compliant, and efficient manner. Activities covered included network optimization, cost of sales management, capacity management, corporate and regional planning, operations strategic planning (long range plan), trade, regional supply chains which include demand management, customer service, distribution, logistics and regional manufacturing, product launches and governance of transformation initiatives. Som is currently responsible for Operations data analytics transformation initiative.
Prior to this role, Som was Vice President of Results Delivery Office reporting to Executive Vice President of Corporate Transformation. He led a selected team to identify, envision, and install improvements to reduce costs and increase operational efficiency. These business cases containing improved strategy, structure, and processes resulted in creation of initiatives which delivered between 2014-2018 >$1.5B cost savings; 15 ppt operating income rise.
Som joined Amgen in 2002 and over the last 16 years has held positions of increasing responsibilities in engineering, strategic planning, results delivery office (finance), and supply chain. Som has worked in Rhode Island, Ireland, and Thousand Oaks.
Prior to joining Amgen, Som worked across the Semiconductor Capital Expansion value chain involved in multiple billion $+ capital expansion projects around the world.
Som has over 30 years of experience in Biotechnology and Semiconductor industry. Som holds a degree in Production and Industrial engineering from MNNIT (Motilal Nehru National Institute of Technology), Allahabad, India and is Professional Engineer -Mechanical in the State of California.